Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Are new technologies translatable to point-of-care testing?

The point-of-care testing (PoCT) market is rapidly expanding and its predicted worth by 2021 is US$36·96 billion.1 This market has many facets, one of which is tumour and cancer markers. To develop a new test for clinical use, a biomarker needs to be identified and a quick and simple detection method developed. This biomarker then goes through many steps before clinical use including the all-important step—can it detect cancer earlier than existing methods?